You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Ramipril reduced mortality and cardiovascular morbidity in high risk adults

https://doi.org/10.1136/ebm.5.2.47

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2000) N Engl J Med 342, 145. The Heart Outcomes Prevention Evaluation Study Investigators.. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients.. Jan 20;. :. –53.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In adults who are at high risk for cardiovascular (CV) events, does ramipril, an angiotensin converting enzyme (ACE) inhibitor, reduce CV events? (Vitamin E results will be reported separately.)

    Design

    Randomised {allocation concealed*}†, blinded (patients, clinicians, and outcome assessors),* controlled 2×2 factorial design trial with planned interim analyses (Heart Outcomes Prevention Evaluation [HOPE] study).

    Setting

    161 centres in North America, 76 in 14 western European countries, and 30 in Argentina and Brazil.

    Participants

    9541 adults (mean age 66 y, 73% men) who were aged ≥55 years and had a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes and ≥1 other CV risk factor. Exclusion criteria were heart failure, ejection fraction <0.4, use of an ACE inhibitor, uncontrolled hypertension, …

    View Full Text